Vimarsana
Biggest News Aggregation in the World

Page 36 - Twist Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Twist Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Twist Bioscience Today - Breaking & Trending Today

Twist Bioscience (NASDAQ:TWST) PT Lowered to $20.00 at Barclays - Vimarsana News

Twist Bioscience (NASDAQ:TWST) PT Lowered to $20.00 at Barclays

Twist Bioscience (NASDAQ:TWST – Get Rating) had its target price reduced by Barclays from $32.00 to $20.00 in a research report released on Monday morning, The Fly reports. Several other research firms have also recently issued reports on TWST. The Goldman Sachs Group reduced their price objective on shares of Twist Bioscience from $43.00 to […]

Twist Bioscience (NASDAQ:TWST) PT Lowered to $18.00 - Vimarsana News

Twist Bioscience (NASDAQ:TWST) PT Lowered to $18.00

Twist Bioscience (NASDAQ:TWST – Get Rating) had its target price lowered by Robert W. Baird from $29.00 to $18.00 in a report released on Monday, The Fly reports. A number of other research analysts have also recently weighed in on TWST. The Goldman Sachs Group dropped their price target on Twist Bioscience from $43.00 to […]

Twist Bioscience (NASDAQ:TWST) PT Lowered to $20.00 at Barclays - Vimarsana News

Twist Bioscience (NASDAQ:TWST) PT Lowered to $20.00 at Barclays

Twist Bioscience (NASDAQ:TWST – Get Rating) had its price target lowered by Barclays from $32.00 to $20.00 in a research report released on Monday morning, The Fly reports. A number of other analysts have also recently weighed in on the stock. The Goldman Sachs Group decreased their price target on shares of Twist Bioscience from […]

Twist Bioscience (NASDAQ:TWST) Price Target Cut to $18.00 - Vimarsana News

Twist Bioscience (NASDAQ:TWST) Price Target Cut to $18.00

Twist Bioscience (NASDAQ:TWST – Get Rating) had its price target lowered by analysts at Robert W. Baird from $29.00 to $18.00 in a research report issued on Monday, The Fly reports. Robert W. Baird’s target price would suggest a potential upside of 33.14% from the stock’s current price. Several other equities analysts have also recently […]

GeneDx Q1 Revenues Fall 20 Percent but Beat Consensus Estimate - Vimarsana News

GeneDx Q1 Revenues Fall 20 Percent but Beat Consensus Estimate

Molecular diagnostic testing volume grew across all continuing operations in Q1 as GeneDx completed the shutdown of underperforming Sema4 assets.

Source: 360dx.com